New drug combo aims to boost head and neck cancer treatment

NCT ID NCT05366166

Ongoing Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jan 30, 2026 · Last updated May 05, 2026 · Updated 11 times

Summary

This study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help people with locally advanced head and neck cancer live longer without the disease getting worse. About 45 adults will take part. The goal is to see if this combination improves cancer control compared to standard treatment alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Indiana University Simon Comprehensive Cancer Center

Indianapolis, Indiana, 46202, United States
Medical University of South Carolina (MUSC)

Charleston, South Carolina, 29425, United States
UNC Lineberger

Chapel Hill, North Carolina, 27514, United States
University of Louisville, Brown Cancer Center

Louisville, Kentucky, 40202, United States

Conditions

Explore the condition pages connected to this study.

SQUAMOUS CELL CARCINOMA OF HEAD AND NECK